Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CNTG 
Centogene B V (CNTG)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/20/2025: CNTG (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -65.69% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/20/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 9.43M USD | Price to earnings Ratio - | 1Y Target Price 1.52 |
Price to earnings Ratio - | 1Y Target Price 1.52 | ||
Volume (30-day avg) 248566 | Beta -0.67 | 52 Weeks Range 0.04 - 0.55 | Updated Date 06/22/2025 |
52 Weeks Range 0.04 - 0.55 | Updated Date 06/22/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.39 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -73.21% | Operating Margin (TTM) -63.29% |
Management Effectiveness
Return on Assets (TTM) -26.76% | Return on Equity (TTM) -1375.33% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 75760700 | Price to Sales(TTM) 0.19 |
Enterprise Value 75760700 | Price to Sales(TTM) 0.19 | ||
Enterprise Value to Revenue 1.36 | Enterprise Value to EBITDA -1.58 | Shares Outstanding 29000100 | Shares Floating 11780726 |
Shares Outstanding 29000100 | Shares Floating 11780726 | ||
Percent Insiders 4.57 | Percent Institutions 66.89 |
Analyst Ratings
Rating 4 | Target Price 1.51 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Centogene B V
Company Overview
History and Background
Centogene B.V., founded in 2006, is a rare disease company focused on genetic diagnostics. They offer genetic testing services, data-driven insights, and therapeutic development for rare diseases.
Core Business Areas
- Diagnostic Services: Genetic testing for rare diseases, including whole exome sequencing, gene panel testing, and biochemical analyses.
- Pharmaceutical Partnerships: Collaborations with pharmaceutical companies to develop and market therapies for rare diseases.
- Data Solutions: Providing data-driven insights to healthcare providers and pharmaceutical companies based on its proprietary rare disease database.
Leadership and Structure
The leadership team comprises experienced professionals in genetics, diagnostics, and pharmaceuticals. The organizational structure includes departments for diagnostics, research and development, commercial operations, and corporate functions.
Top Products and Market Share
Key Offerings
- CentoXome: Whole exome sequencing service for rare disease diagnosis. Market share data is not readily available publicly. Competitors include Invitae (NVTA), Myriad Genetics (MYGN), and Quest Diagnostics (DGX).
- CentoPanel: Gene panel testing for specific rare disease indications. Market share data is not readily available publicly. Competitors include Invitae (NVTA), Myriad Genetics (MYGN), and Quest Diagnostics (DGX).
- Bio/Pharma Services: Partnerships with pharmaceutical companies for drug development, clinical trials, and data analytics for rare diseases. Market share data is unavailable. Competitors include contract research organizations (CROs) such as IQVIA (IQV) and Labcorp (LH).
Market Dynamics
Industry Overview
The genetic testing market is growing rapidly, driven by technological advancements and increasing awareness of rare diseases. The pharmaceutical industry is also investing heavily in rare disease therapies.
Positioning
Centogene positions itself as a leading provider of genetic diagnostics and data-driven insights for rare diseases, with a focus on difficult-to-diagnose cases and partnerships with pharmaceutical companies.
Total Addressable Market (TAM)
The global rare disease diagnostics and therapeutics market is estimated to be in the billions of dollars. Centogene is positioned to capture a portion of this market through its diagnostic services and pharmaceutical partnerships.
Upturn SWOT Analysis
Strengths
- Proprietary rare disease database
- Expertise in genetic diagnostics
- Partnerships with pharmaceutical companies
- Global presence
Weaknesses
- High operating expenses
- History of financial losses
- Dependence on pharmaceutical partnerships
- Competition from larger diagnostic companies
Opportunities
- Expanding genetic testing market
- Increasing demand for rare disease therapies
- Growth in personalized medicine
- Potential for new pharmaceutical partnerships
Threats
- Competition from larger diagnostic companies
- Pricing pressure in genetic testing
- Regulatory changes
- Economic downturns
Competitors and Market Share
Key Competitors
- NVTA
- MYGN
- DGX
- IQV
- LH
Competitive Landscape
Centogene has a specialized focus on rare diseases and a proprietary database, which are advantages. However, it faces competition from larger, more diversified diagnostic companies with greater resources and wider market reach.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by increased demand for genetic testing and pharmaceutical partnerships. However, the company has also faced financial challenges.
Future Projections: Future growth is expected to be driven by the expansion of the genetic testing market and the development of new rare disease therapies. Analyst estimates may vary depending on market conditions.
Recent Initiatives: Recent initiatives have focused on expanding diagnostic services, strengthening pharmaceutical partnerships, and improving operational efficiency.
Summary
Centogene B.V. is a niche player in the rare disease genetic diagnostics market. It leverages its proprietary database and pharmaceutical partnerships. However, the company faces strong competition from larger diagnostic firms and has a history of financial losses, requiring vigilance. Growth depends on market expansion and successful partnerships.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Industry reports
- Market research reports
- Financial news sources
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Market share data is based on publicly available information and may not be precise. Financial data may be limited without access to a financial data provider.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Centogene B V
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2019-11-07 | CEO & Member of Management Board Ms. Kim Stratton | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 384 | Website https://www.centogene.com |
Full time employees 384 | Website https://www.centogene.com | ||
Centogene N.V., together with its subsidiaries, provides pharmaceutical solutions and diagnostic tests in Europe, the Middle East, North America, Latin America, and the Asia Pacific. The company offers data-driven answers to patients, physicians, and pharmaceutical companies for rare and neurodegenerative diseases. It provides CENTOGENE MOx 2.0, a single-step multiomic solution that combines DNA sequencing, biochemical testing, and RNA sequencing; CentoCloud, a cloud-based Software as a Service platform, which enables laboratories to analyze, interpret, and report genomic variants for rare disease diagnostics; FilterTool, a web-based application for genetic data interpretation; and NEW CentoGenome, a Next Generation Sequencing (NGS)-based assay that provides diagnostic information to accelerate access to potential treatment options. The company also offers target and drug screening, clinical development, and market access and expansion, as well as CENTOGENE Biodatabank licenses and insight reports. In addition, it provides early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services, such as whole exome sequencing, whole genome sequencing, and multiomic testing solutions to physicians, laboratories, and hospitals directly or through distributors. The company was founded in 2006 and is headquartered in Rostock, Germany.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.